Relationship Between Plasma NFL and Disease Progression in Parkinson's Disease: a Prospective Cohort Study

Overview

Journal J Neurol

Specialty Neurology

Date 2023 Dec 8

PMID 38063869

Authors

Ruwei Ou

Kuncheng Liu

Junyu Lin

Tianmi Yang

Yi Xiao

Qianqian Wei

Yanbing Hou

Chunyu Li

Lingyu Zhang

Zheng Jiang

Bi Zhao

Xueping Chen

Wei Song

Ying Wu

Huifang Shang

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to examine the longitudinal change of plasma neurofilament light chain (NFL) level and explore its diagnostic and prognostic implications in Parkinson's disease (PD).

Methods: A total of 184 patients with early PD who completed 5-year annually repeated clinical assessments were included. Plasma NFL at baseline, 1 year, and 2 year were examined, which were quantified using the ultrasensitive Simoa technology. At baseline, blood from 86 sex- and age-matched healthy controls (HC) were obtained for comparison.

Results: Plasma NFL in PD patients at baseline was significantly higher than those in HC (P = 0.046), and significantly increased after 2 years (P = 0.046). Receiver operating characteristic curve indicated that a plasma NFL cut-off value of 10.79 pg/mL resulted in 39.7% sensitivity and 84.0% specificity, with an area under the curve of 0.635, to distinguish PD from HC (P < 0.001). Linear mixed-effect models indicated that baseline plasma NFL (> 9.24 pg/mL) correlated with a greater increase in the Unified Parkinson's Disease Rating Scale III (estimate = 0.651, P = 0.001) and Hoehn & Yahr stage (estimate = 0.072, P < 0.001), and also correlated with a greater decrease in the Montreal Cognitive Assessment (estimate = - 0.387, P < 0.001) during follow-up visits.

Conclusions: Plasma NFL exhibits a tendency to increase with disease progression, and elevated baseline plasma NFL can serve as a predictor for accelerated motor deterioration and cognitive decline in PD. However, plasma NFL does not have high accuracy to distinguish individuals with early-stage PD from HC.

Citing Articles

Effects of long-term almond consumption on markers for vascular function and cardiometabolic risk in men and women with prediabetes: results of a randomized, controlled cross-over trial.

Chavez-Alfaro M, Mensink R, Gravesteijn E, Joris P, Plat J Eur J Nutr. 2024; 64(1):7.

PMID: 39546040 DOI: 10.1007/s00394-024-03510-y.

The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis.

Ye L, Greten S, Wegner F, Doll-Lee J, Krey L, Heine J J Neurol. 2024; 271(5):2639-2648.

PMID: 38353748 PMC: 11055732. DOI: 10.1007/s00415-024-12207-5.

References

Aamodt W, Waligorska T, Shen J, Tropea T, Siderowf A, Weintraub D . Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Mov Disord. 2021; 36(12):2945-2950. PMC: 8688198. DOI: 10.1002/mds.28779. View

Arai H, Schmidt M, Lee V, Hurtig H, Greenberg B, Adler C . Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease. Neurology. 1992; 42(7):1315-22. DOI: 10.1212/wnl.42.7.1315. View

Bacioglu M, Maia L, Preische O, Schelle J, Apel A, Kaeser S . Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016; 91(1):56-66. DOI: 10.1016/j.neuron.2016.05.018. View

Backstrom D, Granasen G, Domellof M, Linder J, Jakobson Mo S, Riklund K . Early predictors of mortality in parkinsonism and Parkinson disease: A population-based study. Neurology. 2018; 91(22):e2045-e2056. PMC: 6282235. DOI: 10.1212/WNL.0000000000006576. View

Backstrom D, Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M . Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurol. 2015; 72(10):1175-82. DOI: 10.1001/jamaneurol.2015.1449. View

Cochrane C, Ebmeier K . Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology. 2013; 80(9):857-64. PMC: 3598454. DOI: 10.1212/WNL.0b013e318284070c. View

Fereshtehnejad S, Zeighami Y, Dagher A, Postuma R . Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain. 2017; 140(7):1959-1976. DOI: 10.1093/brain/awx118. View

Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S . Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA Neurol. 2017; 74(5):525-532. PMC: 5822207. DOI: 10.1001/jamaneurol.2016.5398. View

Halliday G, Hely M, Reid W, Morris J . The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 2008; 115(4):409-15. DOI: 10.1007/s00401-008-0344-8. View

10.

Hamilton M . The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1):50-5. DOI: 10.1111/j.2044-8341.1959.tb00467.x. View

11.

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees A, Andreasson U . Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017; 88(10):930-937. PMC: 5333515. DOI: 10.1212/WNL.0000000000003680. View

12.

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

13.

Khalil M, Teunissen C, Otto M, Piehl F, Sormani M, Gattringer T . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018; 14(10):577-589. DOI: 10.1038/s41582-018-0058-z. View

14.

Lin C, Li C, Yang K, Lin F, Wu C, Chieh J . Blood NfL: A biomarker for disease severity and progression in Parkinson disease. Neurology. 2019; 93(11):e1104-e1111. DOI: 10.1212/WNL.0000000000008088. View

15.

Macleod A, Taylor K, Counsell C . Mortality in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014; 29(13):1615-22. DOI: 10.1002/mds.25898. View

16.

Moberg P, Lazarus L, Mesholam R, Bilker W, Chuy I, Neyman I . Comparison of the standard and structured interview guide for the Hamilton Depression Rating Scale in depressed geriatric inpatients. Am J Geriatr Psychiatry. 2001; 9(1):35-40. View

17.

Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H . Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. Mov Disord. 2020; 35(11):1999-2008. PMC: 8017468. DOI: 10.1002/mds.28206. View

18.

Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View

19.

Ng A, Tan Y, Yong A, Saffari S, Lu Z, Ng E . Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease. Mol Neurodegener. 2020; 15(1):33. PMC: 7275464. DOI: 10.1186/s13024-020-00385-5. View

20.

Oosterveld L, Verberk I, Majbour N, El-Agnaf O, Weinstein H, Berendse H . CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls. Mov Disord. 2019; 35(2):288-295. PMC: 7027879. DOI: 10.1002/mds.27897. View